The Role of AKR1B10 in Physiology and Pathophysiology

Overview

Journal Metabolites

Publisher MDPI

Date 2021 Jun 2

PMID 34063865

Citations 34

Authors

Satoshi Endo

Toshiyuki Matsunaga

Toru Nishinaka

Affiliations

Soon will be listed here.

Abstract

AKR1B10 is a human nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reductase belonging to the aldo-keto reductase (AKR) 1B subfamily. It catalyzes the reduction of aldehydes, some ketones and quinones, and interacts with acetyl-CoA carboxylase and heat shock protein 90α. The enzyme is highly expressed in epithelial cells of the stomach and intestine, but down-regulated in gastrointestinal cancers and inflammatory bowel diseases. In contrast, AKR1B10 expression is low in other tissues, where the enzyme is upregulated in cancers, as well as in non-alcoholic fatty liver disease and several skin diseases. In addition, the enzyme's expression is elevated in cancer cells resistant to clinical anti-cancer drugs. Thus, growing evidence supports AKR1B10 as a potential target for diagnosing and treating these diseases. Herein, we reviewed the literature on the roles of AKR1B10 in a healthy gastrointestinal tract, the development and progression of cancers and acquired chemoresistance, in addition to its gene regulation, functions, and inhibitors.

Citing Articles

Joint exploration of network pharmacology and metabolomics on the effects of traditional Chinese medicine compounds in weaned yaks.

Lu S, Zhu Y, Zhang X, Cidan Y, Basang W, Li K Front Vet Sci. 2025; 11():1511311.

PMID: 39872609 PMC: 11770994. DOI: 10.3389/fvets.2024.1511311.

Development of a Novel four-gene Model for Monitoring the Progression from Metabolic Dysfunction-associated Steatotic Liver Disease to Hepatocellular Carcinoma in Males.

Jiang Y, Chen J, Xu L, Lv L, Gan X J Cancer. 2025; 16(3):917-931.

PMID: 39781352 PMC: 11705051. DOI: 10.7150/jca.100724.

Identification and validation of Novel Estrogen Biosynthesis Biomarkers in Sinonasal Inverted Papilloma.

Yang Y, Yu S, Liao J, Lin Y Int J Med Sci. 2025; 22(1):158-169.

PMID: 39744163 PMC: 11659834. DOI: 10.7150/ijms.101753.

AKR1B10 and digestive tumors development: a review.

Shen Y, Qiu A, Huang X, Wen X, Shehzadi S, He Y Front Immunol. 2024; 15:1462174.

PMID: 39737179 PMC: 11682995. DOI: 10.3389/fimmu.2024.1462174.

Development of a novel diagnostic model to monitor the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma in females.

Gan X, Zhou Y, Li Y, Xu L, Liu G Discov Oncol. 2024; 15(1):812.

PMID: 39699604 PMC: 11659565. DOI: 10.1007/s12672-024-01636-3.

References

Reddy K, Uday Kumar P, Srinivasulu M, Triveni B, Sharada K, Ismail A . Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers. Breast. 2016; 31:137-143. DOI: 10.1016/j.breast.2016.11.003. View

Kang M, Lee E, Yoon S, Jo J, Lee J, Kim H . AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer. J Int Med Res. 2011; 39(1):78-85. DOI: 10.1177/147323001103900110. View

Liu X, Hu Z, Qu J, Li J, Gong K, Wang L . AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-κB axis in nasopharyngeal carcinoma. Int J Biol Sci. 2021; 17(3):756-767. PMC: 7975703. DOI: 10.7150/ijbs.52927. View

Liu Y, Zhang J, Liu H, Guan G, Zhang T, Wang L . Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis. Am J Cancer Res. 2020; 9(12):2730-2748. PMC: 6943354. View

Penning T . The aldo-keto reductases (AKRs): Overview. Chem Biol Interact. 2014; 234:236-46. PMC: 4388799. DOI: 10.1016/j.cbi.2014.09.024. View

Yao Y, Wang X, Zhou D, Li H, Qian H, Zhang J . Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway. Aging (Albany NY). 2020; 12(13):13059-13075. PMC: 7377871. DOI: 10.18632/aging.103393. View

Yao H, Xu Y, Chen L, Guan T, Ma Y, He X . AKR1B10, a good prognostic indicator in gastric cancer. Eur J Surg Oncol. 2014; 40(3):318-24. DOI: 10.1016/j.ejso.2013.12.014. View

Pettinelli P, Arendt B, Teterina A, McGilvray I, Comelli E, Fung S . Altered hepatic genes related to retinol metabolism and plasma retinol in patients with non-alcoholic fatty liver disease. PLoS One. 2018; 13(10):e0205747. PMC: 6209208. DOI: 10.1371/journal.pone.0205747. View

Yan R, Zu X, Ma J, Liu Z, Adeyanju M, Cao D . Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int J Cancer. 2007; 121(10):2301-6. DOI: 10.1002/ijc.22933. View

10.

Pastel E, Pointud J, Volat F, Martinez A, Lefrancois-Martinez A . Aldo-Keto Reductases 1B in Endocrinology and Metabolism. Front Pharmacol. 2012; 3:148. PMC: 3410611. DOI: 10.3389/fphar.2012.00148. View

11.

Feng G, Li X, Niu C, Liu M, Yan Q, Fan L . Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Gene. 2020; 742:144549. DOI: 10.1016/j.gene.2020.144549. View

12.

Endo S, Matsunaga T, Soda M, Tajima K, Zhao H, El-Kabbani O . Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. Biol Pharm Bull. 2010; 33(5):886-90. DOI: 10.1248/bpb.33.886. View

13.

MacLeod A, Acosta-Jimenez L, Coates P, McMahon M, Carey F, Honda T . Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer. Br J Cancer. 2016; 115(12):1530-1539. PMC: 5155360. DOI: 10.1038/bjc.2016.363. View

14.

Morikawa Y, Kezuka C, Endo S, Ikari A, Soda M, Yamamura K . Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10. Chem Biol Interact. 2015; 230:30-9. DOI: 10.1016/j.cbi.2015.02.005. View

15.

Singh M, Kapoor A, Bhatnagar A . Oxidative and reductive metabolism of lipid-peroxidation derived carbonyls. Chem Biol Interact. 2015; 234:261-73. PMC: 4414726. DOI: 10.1016/j.cbi.2014.12.028. View

16.

Dai G, Wang L, Wen Y, Ren X, Zuo S . Identification of key genes for predicting colorectal cancer prognosis by integrated bioinformatics analysis. Oncol Lett. 2020; 19(1):388-398. PMC: 6924121. DOI: 10.3892/ol.2019.11068. View

17.

Hara A, Endo S, Matsunaga T, Soda M, El-Kabbani O, Yashiro K . Inhibition of aldo-keto reductase family 1 member B10 by unsaturated fatty acids. Arch Biochem Biophys. 2016; 609:69-76. DOI: 10.1016/j.abb.2016.09.010. View

18.

Li C, Goto A, Watanabe A, Murata K, Ota S, Niki T . AKR1B10 in usual interstitial pneumonia: expression in squamous metaplasia in association with smoking and lung cancer. Pathol Res Pract. 2008; 204(5):295-304. DOI: 10.1016/j.prp.2006.12.012. View

19.

Tebay L, Robertson H, Durant S, Vitale S, Penning T, Dinkova-Kostova A . Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med. 2015; 88(Pt B):108-146. PMC: 4659505. DOI: 10.1016/j.freeradbiomed.2015.06.021. View

20.

Henriksson M, Edin S, Dahlin A, Oldenborg P, Oberg A, van Guelpen B . Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. Am J Pathol. 2011; 178(3):1387-94. PMC: 3070577. DOI: 10.1016/j.ajpath.2010.12.008. View